



Biomarkers of AD

1. Holtzman. CSF Biomarkers for Alzheimer's Disease: current utility and potential future use. *Neurobiol Aging* (2011) 32:S4–S9
2. Hardy and Selkoe. The Amyloid Hypothesis of Alzheimer's Disease: progress and problems on the road to therapeutics. *Science* (2002) 297:353-356
3. Sunderland *et al.*, Decreased β -Amyloid₁₋₄₂ and Increased Tau Levels in Cerebrospinal Fluid of Patients with Alzheimer Disease. *JAMA* (2003) 289:2094-2103
4. Blennow and Hampel. CSF Markers for Incipient Alzheimer's Disease. *Lancet Neurol* (2003) 2:605-13
5. Blennow. Cerebrospinal Fluid Protein Biomarkers for Alzheimer's disease. *NeuroRx* (2004) 1:213-25
6. Fagan *et al.*, Inverse Relation between In Vivo Amyloid Imaging Load and Cerebrospinal Fluid A β ₄₂ in Humans. *Ann Neurol* (2006) 59:512-519
7. Fagan *et al.*, Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. *EMBO Mol. Med.* 1, 371-380
8. Fagan *et al.*, Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. *Arch Neurol* (2007) 64:343-349
9. Tapiola *et al.*, Cerebrospinal Fluid β -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. *Arch Neurol* (2009) 66:382-389
10. Arai *et al.*, Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. *Biochem Biophys Res. Commun* (1997) 236:262-264
11. Arai *et al.*, CSF Phosphorylated tau protein and mild cognitive impairment: a prospective study. *Exp Neurol.* (2000) 166:201-203

Why use cerebrospinal fluid biomarkers for AD dementia diagnosis?

1. McKhann et al., The Diagnosis of Dementia due to Alzheimer's Disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer Dement* (2011) 7: 263-269
2. Bouman et al., New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. *Dement Geriatr Cogn Disord* (2010) 30: 1-7
3. Blennow and Hampel. CSF Markers for Incipient Alzheimer's Disease. *Lancet Neurol* (2003) 2:605-13
4. Blennow et al., CSF Biomarkers for Mild Cognitive Impairment. *J Intern Med* (2004) 256:224-234
5. Blennow et al., CSF Biomarkers for Alzheimer's Disease: use in early diagnosis and evaluation of drug treatment. *Exper Rev Mol Diagn* (2005) 5:661-672
6. Hampel . Identifying and Validating Biomarkers for Alzheimer's Disease. *Trends Biotechnol* (2011) 29(1):26-32

CSF biomarker analysis increases diagnostic certainty

1. McKhann et al., The Diagnosis of Dementia due to Alzheimer's Disease: Recommendations from the National Institute on Ageing-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer Dement* (2011) 7: 263-269
2. Buchave et al., Cerebrospinal fluid levels of β -amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Arch Gen Psychiatry* (2012) 69(1): 98-106
3. Hansson et al., Biomarkers for the Early Diagnosis of Alzheimer's Disease. *Lancet Neurol* (2006) 5: 228-234
4. Kester et al., Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic. *Dement Geriatr Cogn Disord* (2010) 29: 491-497

Why measure AD biomarkers in CSF and not blood

1. Redzic. Molecular Biology of the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers: similarities and differences. *Fluids and barriers of the CNS* (2011) 8(1):3
2. Anoop et al., CSF Biomarkers for Alzheimer's Disease Diagnosis. *Int J Alzheimer Dis* (2010) 2010:606802
3. Duits et al., (2016) Performance and Complications of Lumbar Puncture in Memory Clinics: Results of the multicenter lumbar puncture feasibility study. *Alzheimer Dement* (2016) 12(2), 1-10.

Lumbar puncture execution

1. Mattsson et al., Lessons from Multicentre Studies on CSF biomarkers for Alzheimer's Disease. *Int J Alzheimers Dis* (2010)610613: 1-5
2. Vanderstichele et al., Standardisation of Preanalytical Aspects of Cerebrospinal Fluid Biomarker Testing for Alzheimer's Disease Diagnosis. A consensus paper from the Alzheimer's Biomarker Standardization Initiative. *Alzheimer Dement* (2012)8: 65-73
3. Duits et al., (2016) Performance and Complications of Lumbar Puncture in Memory Clinics: Results of the multicenter lumbar puncture feasibility study. *Alzheimer Dement* (2016) 12(2), 1-10.
4. Adapted from: Blennow (2009) <http://www.alzforum.org/protocols/alzheimers-association-flow-chart-lumbar-puncture-csf-processing-0>

CSF processing and biomarker analysis

1. Lewczuk et al., International Quality Control Survey of Neurochemical Dementia Diagnostics. *Neurosci Lett* (2006)409: 1-4
2. Verwey et al., A Worldwide Multicentre Comparison of Essays for Cerebrospinal fluid Biomarkers in Alzheimer's Disease. *Ann Clin Biochem* (2009)46: 235-240
3. Mattsson et al., The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. *Alzheimers Dement* (2011)7: 386—395
4. Del Campo et al., Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. *Biomarkers Med* (2012)6(4):419-430
5. Mattsson et al., Lessons from multicentre studies on CSF biomarkers for Alzheimer's disease. *Int J Alzheimer Dis* (2010) 610613: 1-5
6. Vanderstichele et al., Standardisation of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis. A consensus paper from the Alzheimer's Biomarker Standardization Initiative. *Alzheimer Dement* (2012)8: 65-73
7. Teunissen et al., A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. *Neurology* (2009)73: 1914-22
8. Mattsson et al., CSF biomarker variability in the Alzheimer's Association quality control program. *Alzheimer Dement* (2013) 9(3): 251-261

Benefits of an early diagnosis and disclosure

1. Cahill et al. *Creating Excellence in Dementia Care*. DSIDC publication (2012): http://dementia.ie/images/uploads/siteimages/creating_excellence_in_dementia_care_2012.pdf
2. Irish National Dementia Strategy: health.gov.ie/.../2014/12/30115-National-Dementia-Strategy-Eng.pdf
3. Alzheimer Disease International: World Alzheimer Report (2011): <http://www.alz.co.uk/research/WorldAlzheimerReport2011.pdf>
4. Pinner G et al. Attitudes of Patients With Mild Dementia and Their Carers Towards Disclosure of the Diagnosis. *Int Psychogeriatr* (2003) 15(3):279-288
5. Connell CM et al. Attitudes Toward the Diagnosis and Disclosure of Dementia Among Family Caregivers and Primary Care Physicians. *Gerontologist* (2004) 44(4):500-507
6. Carpenter BD et al. Reaction to a Dementia Diagnosis in Individuals With Alzheimer's Disease and Mild Cognitive Impairment. *J Am Geriatr Soc* (2008) 56(3):405-412
7. Derksen E et al. Impact of diagnostic disclosure in dementia on patients and carers: Qualitative case series analysis. *Aging Ment Health* (2006); 10(5):525-531.
8. Molinuevo et al., The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement* (2014) 10: 808-817

Consensus Guidelines and results interpretation / disclosure

1. Hort et al., EFNS Guidelines for the Diagnosis and Management of Alzheimer's Disease *Eur J Neurol* (2010)**17**: 1236-1248.
2. National Institute for Health and Clinical Excellence – Social Care Institute for Excellence: Dementia NICE clinical guideline 42 2006: Available at: <http://www.nice.org.uk/guidance/conditions-and-diseases/neurological-conditions/dementia>
3. Rosa-Neto et al., Fluid Biomarkers for Diagnosing Dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. *Alzheimer's Research and Therapy* (2013)5(Suppl 1):S8
4. Molinuevo et al., The Clinical use of Cerebrospinal Fluid Biomarker testing for Alzheimer's Disease Diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimer & Dement* (2014)10: 808-817
5. Dubois et al., Research Criteria for the Diagnosis of Alzheimer's Disease: revising the NINCDS–ADRDA criteria. *Lancet Neurol* (2007) 6: 734 – 746
6. Dubois et al., Advancing Research Diagnostic Criteria for Alzheimer's Disease: the IWG-2 criteria. *Lancet Neurol* (2014) 13: 614 – 629
7. Duits et al., The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean? *Alzheimer Dement* (2014) 10(6): 713 - 723

Interpretation

1. McKhann et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* (1984) 34: 939-944.
2. McKhann et al., The Diagnosis of Dementia due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* (2011) 7: 263-
3. Molinuevo et al. The Clinical use of Cerebrospinal Fluid Biomarker testing for Alzheimer's Disease Diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement* (2014)10: 808-817.

Dementia types overview

The dementias: Hope through Research, NIH publication (2015)

<https://www.nia.nih.gov/alzheimers/publication/dementias>

Atypical:

1. Dubois B et al. Revising the definition of Alzheimer's disease: a new lexicon. *Lancet Neurol.* (2010) 9:1118–1127
2. Lladó A et al. Focusing on Atypical Symptoms for Improved Diagnosis of Early-onset Alzheimer's Disease. *Future Neurology* (2011) 6:5: 575-578

Early Onset:

1. Snowden JS et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. *Brain* (2011) 134(Pt 9):478-492
2. Vieira RT et al. Epidemiology of early-onset dementia: a review of the literature. *Clinical Practice Epidemiology Mental Health* (2013) 14(9): 88-95
3. Lambert MA et al., Estimating the burden of early onset dementia: systematic review of disease prevalence. *Eur J Neurol* (2014) 21(4): 563 – 569

Rapidly progressing:

1. Rosenbloom and Atri (2011) The evaluation of rapidly progressing dementia. *Neurologist* 17(2): 67-74
2. Geschwind et al (2008) Rapidly Progressive Dementia. *Neurol Clin* 64(1): 97-108

Testing limitations and results disclosure

1. McKhann et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement* (2011) 7: 263-269
2. Molinuevo et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimer's Dement* (2014)10: 808-817